Across TCGA pan-cancer cohorts, ARL2 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ARL2 data layer compared with 26 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in pancreatic adenocarcinoma (PAAD), where higher ARL2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ARL2 expression acts as an unfavorable survival marker.

PAAD, SARC, and PRAD are the cancer types where ARL2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PAAD	OS	Median	All	0.132	0.590	<.001	12	view →
SARC	DFS	Median	All	0.121	0.611	.041	6	view →
PRAD	DFS	Median	All	0.107	0.886	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: ARL2 tumor-vs-normal RNA expression · all ARL2 data types